Bevespi Aerosphere

Bevespi Aerosphere is a combination inhaler containing glycopyrronium bromide and formoterol fumarate dihydrate. It is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This medication helps improve breathing and reduce symptoms.

Bevespi Aerosphere is primarily used for the long-term management of chronic obstructive pulmonary disease (COPD). It combines two active ingredients, glycopyrronium bromide and formoterol fumarate dihydrate, to help open the airways and make breathing easier. This inhaler is designed for inhalation use and is not intended for immediate relief of sudden breathing problems.

Common effects of Bevespi Aerosphere may include dry mouth, throat irritation, and coughing. Some users might experience headaches or dizziness. These effects are generally mild and temporary. If any effects persist or worsen, it is important to consult a healthcare provider.

Bevespi Aerosphere should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with certain medical conditions, such as heart problems or severe asthma, should discuss their health status with a healthcare provider before using this medication.

Bevespi Aerosphere may interact with other medications, including beta-blockers, anticholinergics, and certain antidepressants. It is important to inform a healthcare provider about all medications being taken to avoid potential interactions. Additionally, the use of alcohol or other substances that affect the central nervous system should be discussed with a healthcare provider.